| pubmed-article:12928540 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0021368 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0221920 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0007589 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0221912 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0028912 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0205464 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0953467 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C1511938 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C1514485 | lld:lifeskim |
| pubmed-article:12928540 | lifeskim:mentions | umls-concept:C0439272 | lld:lifeskim |
| pubmed-article:12928540 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:12928540 | pubmed:dateCreated | 2003-8-20 | lld:pubmed |
| pubmed-article:12928540 | pubmed:abstractText | This study focused on the effects of tacalcitol (1,24 (R) (OH)2D3, TV-02) ointment (20 micro g/g) on cutaneous inflammation, epidermal proliferation, and differentiation and compared them with tacalcitol ointment (2 micro g/g) and other anti-psoriatic ointments using hairless mice. Tacalcitol ointment (0, 2 and 20 micro g/g) significantly inhibited 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced cutaneous inflammation, histopathologically. The effect of tacalcitol ointment (20 micro g/g) on cutaneous inflammation was much stronger than that of tacalcitol ointment (0, 2 micro g/g), and as effective as calcipotriol ointment (50 micro g/g) or betamethasone valerate ointment (1.2 mg/g). Tacalcitol ointment (20 micro g/g) also significantly inhibited TPA-induced myeloperoxidase (MPO) activity, as effectively as calcipotriol ointment (50 micro g/g) or betamethasone valerate ointment (1.2 mg/g). The effect of tacalcitol ointment on epidermal proliferation [ornithine decarboxylase (ODC) activity] and differentiation [transglutaminase (TGase) activity] was dose-dependent from 0 micro g/g to 20 micro g/g. The effect of tacalcitol ointments on epidermal proliferation was significant at the doses of 2 micro g/g and 20 micro g/g, and that on epidermal differentiation was significant at the doses of 0.2 micro g/g or more. The effect of tacalcitol ointment (20 micro g/g) on epidermal differentiation was significantly stronger than tacalcitol ointment (2 micro g/g). In this study, tacalcitol ointment (20 micro g/g) was found to have a marked effect on cutaneous inflammation and improved effect on epidermal differentiation, although tacalcitol ointment (2 micro g/g) also had significant effects on epidermal proliferation and differentiation. These findings support the clinical effectiveness of tacalcitol ointment (20 micro g/g) against psoriasis. | lld:pubmed |
| pubmed-article:12928540 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12928540 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12928540 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12928540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12928540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12928540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12928540 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12928540 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12928540 | pubmed:issn | 0385-2407 | lld:pubmed |
| pubmed-article:12928540 | pubmed:author | pubmed-author:SatoHiroakiH | lld:pubmed |
| pubmed-article:12928540 | pubmed:author | pubmed-author:OhtaTomohiroT | lld:pubmed |
| pubmed-article:12928540 | pubmed:author | pubmed-author:KomoriyaKeiji... | lld:pubmed |
| pubmed-article:12928540 | pubmed:author | pubmed-author:TakagiHidekoH | lld:pubmed |
| pubmed-article:12928540 | pubmed:author | pubmed-author:AsanoSatoshiS | lld:pubmed |
| pubmed-article:12928540 | pubmed:author | pubmed-author:HataJunkoJ | lld:pubmed |
| pubmed-article:12928540 | pubmed:author | pubmed-author:OginoYasuhiro... | lld:pubmed |
| pubmed-article:12928540 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12928540 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:12928540 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12928540 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12928540 | pubmed:pagination | 510-24 | lld:pubmed |
| pubmed-article:12928540 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:meshHeading | pubmed-meshheading:12928540... | lld:pubmed |
| pubmed-article:12928540 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12928540 | pubmed:articleTitle | Pharmacological profiles of high-concentration (20 microg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice. | lld:pubmed |
| pubmed-article:12928540 | pubmed:affiliation | Pharmacological Research Department, Pharmaceuticals Development Research Laboratories, Teijin Institute for Bio-Medical Research, 4-3-2 Asahigaoka, Hino, Tokyo 191-8512, Japan. | lld:pubmed |
| pubmed-article:12928540 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12928540 | pubmed:publicationType | Comparative Study | lld:pubmed |
| literatureCitation:1757_129... | literatureCitation:pubmed | pubmed-article:12928540 | lld:drugbank |
